TY - JOUR
T1 - Diazepam Prodrug Stabilizes Human Aminopeptidase B during Lyophilization
AU - Rautiola, Davin
AU - Updyke, Joel L.
AU - Nelson, Kathryn M.
AU - Siegel, Ronald A.
N1 - Publisher Copyright:
Copyright © 2019 American Chemical Society.
PY - 2020/2/3
Y1 - 2020/2/3
N2 - Human aminopeptidase B (APB) is a labile enzyme that is being investigated as a biocatalyst for intranasal delivery of prodrug/enzyme combinations. Therefore, the stability of APB is a major concern to ensure a viable drug product. Lyophilization is one technique commonly used to extend shelf life of enzymes. However, the lyophilization process itself can cause conformational changes and aggregation, leading to inactivation of enzymes. In this study, we demonstrate the use of the substrate avizafone (AVF), a prodrug for diazepam, as a stabilizer to minimize inactivation of APB during lyophilization. Permutations of APB samples combined with AVF, trehalose, and/or mannitol were snap-frozen and lyophilized, and subsequently reconstituted to measure the activity of APB. Of the formulation permutations, an APB + AVF + trehalose combination resulted in minimum degradation with 71% retention of activity. This was followed by APB + AVF and APB + trehalose with 60 and 56% retention of activity, respectively. In comparison, APB + mannitol and APB alone retained only 16 and 6.4% activity, respectively. Lyophilizates of the APB + AVF + trehalose formulation were subjected to a 6 month accelerated stability study, at the end of which negligible reduction in activity was observed. These results suggest that colyophilization of an enzyme with its substrate can impart stability on par with the commonly used lyoprotectant, trehalose, but the combination of substrate and trehalose provides a greater stabilizing effect than either additive alone.
AB - Human aminopeptidase B (APB) is a labile enzyme that is being investigated as a biocatalyst for intranasal delivery of prodrug/enzyme combinations. Therefore, the stability of APB is a major concern to ensure a viable drug product. Lyophilization is one technique commonly used to extend shelf life of enzymes. However, the lyophilization process itself can cause conformational changes and aggregation, leading to inactivation of enzymes. In this study, we demonstrate the use of the substrate avizafone (AVF), a prodrug for diazepam, as a stabilizer to minimize inactivation of APB during lyophilization. Permutations of APB samples combined with AVF, trehalose, and/or mannitol were snap-frozen and lyophilized, and subsequently reconstituted to measure the activity of APB. Of the formulation permutations, an APB + AVF + trehalose combination resulted in minimum degradation with 71% retention of activity. This was followed by APB + AVF and APB + trehalose with 60 and 56% retention of activity, respectively. In comparison, APB + mannitol and APB alone retained only 16 and 6.4% activity, respectively. Lyophilizates of the APB + AVF + trehalose formulation were subjected to a 6 month accelerated stability study, at the end of which negligible reduction in activity was observed. These results suggest that colyophilization of an enzyme with its substrate can impart stability on par with the commonly used lyoprotectant, trehalose, but the combination of substrate and trehalose provides a greater stabilizing effect than either additive alone.
KW - aminopeptidase B
KW - avizafone
KW - enzyme stabilization
KW - freeze-drying
KW - lyophilization
KW - prodrug
KW - stability
KW - temperature dependence
UR - http://www.scopus.com/inward/record.url?scp=85077705903&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85077705903&partnerID=8YFLogxK
U2 - 10.1021/acs.molpharmaceut.9b00880
DO - 10.1021/acs.molpharmaceut.9b00880
M3 - Article
C2 - 31829605
AN - SCOPUS:85077705903
SN - 1543-8384
VL - 17
SP - 453
EP - 460
JO - Molecular pharmaceutics
JF - Molecular pharmaceutics
IS - 2
ER -